Guardant Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Guardant Health, Inc. on October 9, 2020, covering events occurring on October 6, 2020. The filing details an underwritten public offering of common stock by a selling stockholder, not the Company itself.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics for Guardant Health, Inc. The document focuses exclusively on the terms of a secondary stock offering.
Material Changes and Transaction Details
- Transaction Type: Underwritten public offering of 7,000,000 shares of Common Stock.
- Selling Stockholder: SVF Bluebird (Cayman) Limited.
- Underwriter: J.P. Morgan Securities LLC.
- Offering Price: $102.00 per share.
- Proceeds: The Company will not receive any proceeds from this sale; all proceeds go to the Selling Stockholder.
- Over-Allotment Option: The Underwriter was granted a 30-day option to purchase up to an additional 700,000 shares at the public offering price, less underwriting discounts.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for the Company. It notes that the Underwriting Agreement includes customary representations, warranties, covenants, and indemnification obligations. The text states that the description of the agreement is subject to the full text filed as Exhibit 1.1.
Key Facts for Investor Verification
- Verify that the Company receives zero proceeds from this specific transaction.
- Confirm the total number of shares outstanding post-transaction to assess potential dilution.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific indemnification obligations assumed by the Company.
- Check if the over-allotment option for 700,000 additional shares was exercised within the 30-day window.